726 related articles for article (PubMed ID: 32918399)
21. Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH).
Lee JH; Oh JY; Kim SH; Oh IJ; Lee YH; Lee KW; Lee WH; Kim JH
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33050067
[TBL] [Abstract][Full Text] [Related]
22. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease.
Katsarou A; Moustakas II; Pyrina I; Lembessis P; Koutsilieris M; Chatzigeorgiou A
World J Gastroenterol; 2020 May; 26(17):1993-2011. PubMed ID: 32536770
[TBL] [Abstract][Full Text] [Related]
23. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity.
Yang M; Kimchi ET; Staveley-O'Carroll KF; Li G
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681695
[TBL] [Abstract][Full Text] [Related]
24. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis.
Su Q; Kumar V; Sud N; Mahato RI
Adv Drug Deliv Rev; 2018 Apr; 129():54-63. PubMed ID: 29391222
[TBL] [Abstract][Full Text] [Related]
25. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
[TBL] [Abstract][Full Text] [Related]
26. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice.
Wang B; Zhu X; Yu S; Xue H; Deng L; Zhang Y; Zhang Y; Liu Y
Biochem Biophys Res Commun; 2024 Aug; 722():150170. PubMed ID: 38797152
[TBL] [Abstract][Full Text] [Related]
27. Antifibrotic activity of carbon quantum dots in a human
García-Topete DA; Álvarez-Lee LA; Carballo-López GI; Uriostegui-Campos MA; Guzmán-Uribe C; Castro-Ceseña AB
Biomater Sci; 2024 Feb; 12(5):1307-1319. PubMed ID: 38263852
[TBL] [Abstract][Full Text] [Related]
28. Sauchinone attenuates liver fibrosis and hepatic stellate cell activation through TGF-β/Smad signaling pathway.
Lee JH; Jang EJ; Seo HL; Ku SK; Lee JR; Shin SS; Park SD; Kim SC; Kim YW
Chem Biol Interact; 2014 Dec; 224():58-67. PubMed ID: 25451574
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
Motiño O; Agra N; Brea Contreras R; Domínguez-Moreno M; García-Monzón C; Vargas-Castrillón J; Carnovale CE; Boscá L; Casado M; Mayoral R; Valdecantos MP; Valverde ÁM; Francés DE; Martín-Sanz P
Biochim Biophys Acta; 2016 Sep; 1862(9):1710-23. PubMed ID: 27321932
[TBL] [Abstract][Full Text] [Related]
30. Extracellular vesicles derived from fat-laden hepatocytes undergoing chemical hypoxia promote a pro-fibrotic phenotype in hepatic stellate cells.
Hernández A; Reyes D; Geng Y; Arab JP; Cabrera D; Sepulveda R; Solis N; Buist-Homan M; Arrese M; Moshage H
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165857. PubMed ID: 32512191
[TBL] [Abstract][Full Text] [Related]
31. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
Ozutsumi T; Namisaki T; Shimozato N; Kaji K; Tsuji Y; Kaya D; Fujinaga Y; Furukawa M; Nakanishi K; Sato S; Sawada Y; Saikawa S; Kitagawa K; Takaya H; Kawaratani H; Kitade M; Moriya K; Noguchi R; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245205
[TBL] [Abstract][Full Text] [Related]
32. Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.
Arndt S; Wacker E; Dorn C; Koch A; Saugspier M; Thasler WE; Hartmann A; Bosserhoff AK; Hellerbrand C
Gut; 2015 Jun; 64(6):973-81. PubMed ID: 25011936
[TBL] [Abstract][Full Text] [Related]
33. Chemokine ligand 20 (CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p.
Hanson A; Piras IS; Wilhelmsen D; Still CD; Chu X; Petrick A; Gerhard GS; DiStefano JK
Cytokine; 2019 Nov; 123():154789. PubMed ID: 31352173
[TBL] [Abstract][Full Text] [Related]
34. Microengineered cultures containing human hepatic stellate cells and hepatocytes for drug development.
Davidson MD; Kukla DA; Khetani SR
Integr Biol (Camb); 2017 Aug; 9(8):662-677. PubMed ID: 28702667
[TBL] [Abstract][Full Text] [Related]
35. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress.
Li BH; He FP; Yang X; Chen YW; Fan JG
Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593
[TBL] [Abstract][Full Text] [Related]
36. The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH.
Barbero-Becerra VJ; Giraudi PJ; Chávez-Tapia NC; Uribe M; Tiribelli C; Rosso N
Toxicol In Vitro; 2015 Oct; 29(7):1753-8. PubMed ID: 26187275
[TBL] [Abstract][Full Text] [Related]
37. GDF11 induces mild hepatic fibrosis independent of metabolic health.
Frohlich J; Kovacovicova K; Mazza T; Emma MR; Cabibi D; Foti M; Sobolewski C; Oben JA; Peyrou M; Villarroya F; Soresi M; Rezzani R; Cervello M; Bonomini F; Alisi A; Vinciguerra M
Aging (Albany NY); 2020 Oct; 12(20):20024-20046. PubMed ID: 33126224
[TBL] [Abstract][Full Text] [Related]
38. Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model.
Takegoshi K; Honda M; Okada H; Takabatake R; Matsuzawa-Nagata N; Campbell JS; Nishikawa M; Shimakami T; Shirasaki T; Sakai Y; Yamashita T; Takamura T; Tanaka T; Kaneko S
Oncotarget; 2017 Mar; 8(11):18191-18205. PubMed ID: 28212548
[TBL] [Abstract][Full Text] [Related]
39. Antagonic effect of ghrelin and LEAP-2 on hepatic stellate cell activation and liver fibrosis in obesity-associated nonalcoholic fatty liver disease.
Ezquerro S; Tuero C; Becerril S; Valentí V; Moncada R; Landecho MF; Catalán V; Gómez-Ambrosi J; Mocha F; Silva C; Hanley KP; Escalada J; Frühbeck G; Rodríguez A
Eur J Endocrinol; 2023 Jul; 188(7):564-577. PubMed ID: 37358209
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.
Schwabe RF; Tabas I; Pajvani UB
Gastroenterology; 2020 May; 158(7):1913-1928. PubMed ID: 32044315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
